Bosentan
Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively.
Product Specifications
CAS Number
[147536-97-8]
UNSPSC
12352005
Hazard Statement
H302, H361, H410
Target
Endothelin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/Bosentan.html
Concentration
10mM
Purity
99.98
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=S(NC1=NC(C2=NC=CC=N2)=NC(OCCO)=C1OC3=CC=CC=C3OC)(C4=CC=C(C(C)(C)C)C=C4)=O
Molecular Formula
C27H29N5O6S
Molecular Weight
551.61
Precautions
H302, H361, H410
References & Citations
[1]Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9 (5) :331-50.|[2]Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16 (2) :R86.|[3]Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118 (2) :333-9.|[4]Son GY, et al. Endothelin Regulates Porphyromonas gingivalis-Induced Production of Inflammatory Cytokines. PLoS One. 2016 Dec 28;11 (12) :e0167713.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Acta Pharmacol Sin. 2023 May;44 (5) :984-998.|Am J Physiol Endocrinol Metab. 2019 Sep 1;317 (3) :E548-E558.|Am J Physiol Heart Circ Physiol. 2019 Nov 1;317 (5) :H1166-H1172.|Biomater Res. 2025 Nov 7:29:0280.|Biomater Res. 2025 Oct 22.|Biomed Pharmacother. 2025 Aug:189:118341.|Biopharm Drug Dispos. 2022 Dec;43 (6) :265-271.|bioRxiv. 2023 Apr 22.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|BMC Cancer. 2018 Feb 6;18 (1) :154.|Cell Biol Toxicol. 2021 Dec;37 (6) :873-890.|Cell Death Dis. 2024 May 22;15 (5) :358.|Cells. 2021 Nov 8;10 (11) :3072.|Chem Res Toxicol. 2025 Feb 17;38 (2) :281-295.|Clin Immunol. 2023 Sep:254:109687.|Curr Issues Mol Biol. 2023 Jan 8;45 (1) :555-570.|Department of Physiology and Pathophysiology. 2020 Sep.|Hypertension. 2019 Dec;74 (6) :1409-1419. |J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Feb 1:1252:124443.|J Toxicol Sci. 2024;49 (8) :337-348.|Microcirculation. 2022 Oct;29 (6-7) :e12724.|Patent. US20220288064A1.|Patent. US20220317132A1.|Phytomedicine. 2019 Mar 15:56:175-182.|Phytomedicine. 2023 Dec:121:155054.|PLoS One. 2016 Dec 28;11 (12) :e0167713.|Sci Rep. 2022 Sep 28;12 (1) :16156.|Toxicology. 2020 May 15;437:152445.|Toxicology. 2025 Jun 3:154210.|J Exp Clin Cancer Res. 2025 Feb 21;44 (1) :64.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
